•
Mar 28, 2021

Teleflex Q1 2021 Earnings Report

Teleflex's Q1 2021 revenues increased slightly, with adjusted EPS exceeding expectations, but GAAP EPS decreased due to various adjustments.

Key Takeaways

Teleflex reported a slight increase in revenue for Q1 2021, driven by strong performance in the Americas and Asia. Adjusted EPS exceeded expectations due to higher gross and operating margins. The company raised its full-year revenue and adjusted EPS guidance.

Q1 2021 revenues increased by 0.5% year-over-year to $633.9 million.

GAAP diluted EPS from continuing operations decreased 43.2% to $1.58.

Adjusted diluted EPS from continuing operations increased 5.5% to $2.87.

Full year 2021 revenue and adjusted EPS guidance raised.

Total Revenue
$634M
Previous year: $631M
+0.5%
EPS
$2.87
Previous year: $2.72
+5.5%
Gross Profit
$345M
Previous year: $334M
+3.3%
Cash and Equivalents
$325M
Previous year: $406M
-20.1%
Total Assets
$7.03B
Previous year: $6.7B
+4.9%

Teleflex

Teleflex

Teleflex Revenue by Segment

Teleflex Revenue by Geographic Location

Forward Guidance

Teleflex raised its full year 2021 GAAP revenue growth estimates from a range of between 10.0% and 11.5% over 2020, to a range of between 10.50% and 11.75% over 2020, reflecting our estimate of an approximately 2% favorable impact of foreign currency exchange rate fluctuations. On a constant currency basis, the Company raised its full year 2021 revenue growth estimates from a range of between 8.0% and 9.5% over 2020, to a range of between 8.50% and 9.75% over 2020. The Company lowered its full year 2021 GAAP diluted earnings per share from continuing operations from a range of between $8.15 and $8.25 to a range of between $8.00 and $8.10. The Company raised its full year 2021 adjusted diluted earnings per share from continuing operations from a range of between $12.50 and $12.70 to a range of between $12.65 and $12.85.

Positive Outlook

  • Full year 2021 GAAP revenue growth estimates raised to a range of between 10.50% and 11.75%.
  • Full year 2021 constant currency revenue growth estimates raised to a range of between 8.50% and 9.75%.
  • Full year 2021 revenue growth estimate of 30% associated with its Interventional Urology business reaffirmed.
  • Full year 2021 adjusted diluted earnings per share from continuing operations raised to a range of between $12.65 and $12.85.
  • Forecasted 2021 GAAP revenue growth: 10.50%-11.75%

Challenges Ahead

  • Full year 2021 GAAP diluted earnings per share from continuing operations lowered from a range of between $8.15 and $8.25 to a range of between $8.00 and $8.10.
  • Adverse economic conditions associated with the COVID-19 global health pandemic and the associated financial crisis.
  • Changes in business relationships with and purchases by or from major customers or suppliers.
  • Delays or cancellations in shipments.
  • Demand for and market acceptance of new and existing products.

Revenue & Expenses

Visualization of income flow from segment revenue to net income